批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/07/22 |
SUPPL-48(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2022/06/10 |
SUPPL-43(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/09/24 |
SUPPL-40(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/03/27 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/02/03 |
SUPPL-37(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2014/01/27 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/02/08 |
SUPPL-34(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2012/11/09 |
SUPPL-33(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/11/09 |
SUPPL-30(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/05/06 |
SUPPL-29(补充) |
Approval |
REMS |
N/A
|
|
|
2011/03/25 |
SUPPL-28(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/01/07 |
SUPPL-27(补充) |
Approval |
REMS |
N/A
|
|
|
2010/07/20 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/01/13 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/06/24 |
SUPPL-17(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2007/08/16 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/04/13 |
SUPPL-15(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/02/24 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/05/24 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/12/22 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/07/29 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/31 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/20 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2002/03/27 |
SUPPL-7(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2001/05/17 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2001/02/23 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2000/11/06 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2000/08/10 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/10/25 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1998/09/11 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
001 |
5366972 |
2011/11/22 |
|
|
|
|
|
PDF格式 | **本条是由Drugfuture回溯的历史信息** |
5366972*PED |
2012/05/22 |
|
|
|
|
|
PDF格式 | **本条是由Drugfuture回溯的历史信息** |
与本品治疗等效的药品
活性成分:NEVIRAPINE 剂型/给药途径:SUSPENSION;ORAL 规格:50MG/5ML 治疗等效代码:AA
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020933 |
001 |
NDA |
VIRAMUNE |
NEVIRAPINE |
SUSPENSION;ORAL |
50MG/5ML |
Discontinued |
Yes |
No |
AA |
1998/09/11
|
BOEHRINGER INGELHEIM |
077702 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
SUSPENSION;ORAL |
50MG/5ML |
Prescription |
No |
Yes |
AA |
2012/05/22
|
AUROBINDO |
207684 |
001 |
ANDA |
NEVIRAPINE |
NEVIRAPINE |
SUSPENSION;ORAL |
50MG/5ML |
Prescription |
No |
No |
AA |
2017/08/03
|
CIPLA |